Insight Molecular Diagnostics Inc. (IMDX)
NASDAQ: IMDX · Real-Time Price · USD
3.190
-0.180 (-5.34%)
At close: Jun 27, 2025, 4:00 PM
3.160
-0.030 (-0.94%)
After-hours: Jun 27, 2025, 7:14 PM EDT
IMDX Revenue
Insight Molecular Diagnostics had revenue of $2.14M in the quarter ending March 31, 2025, with 1,114.77% growth. This brings the company's revenue in the last twelve months to $3.84M, up 178.08% year-over-year. In the year 2024, Insight Molecular Diagnostics had annual revenue of $1.88M with 25.15% growth.
Revenue (ttm)
$3.84M
Revenue Growth
+178.08%
P/S Ratio
15.28
Revenue / Employee
$78,429
Employees
49
Market Cap
91.23M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.88M | 378.00K | 25.15% |
Dec 31, 2023 | 1.50M | 545.00K | 56.89% |
Dec 31, 2022 | 958.00K | -1.24M | -56.41% |
Dec 31, 2021 | 2.20M | 982.00K | 80.76% |
Dec 31, 2020 | 1.22M | - | - |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
IMDX News
- 4 days ago - iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing - GlobeNewsWire
- 10 days ago - Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville - GlobeNewsWire
- 5 weeks ago - Medicare Boosts Reimbursement for Oncocyte's Flagship Technology - GlobeNewsWire
- 6 weeks ago - OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Oncocyte Reports Q1 2025 Results and Business Progress - GlobeNewsWire
- 7 weeks ago - Oncocyte to Release First Quarter 2025 Results on May 12, 2025 - GlobeNewsWire
- 2 months ago - Oncocyte Provides Positive Update on Clinical Trial Progress - GlobeNewsWire
- 2 months ago - Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity - GlobeNewsWire